A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults

A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults

<b>Background/Objectives:</b> Circulating influenza strains antigenically differing from vaccine antigens increase disease burden by decreasing vaccine efficacy. Nucleoside-modified mRNA (modRNA) influenza vaccines may facilitate rapid production allowing later antigen selection and impr...

Full description

Saved in:
Bibliographic Details
Main Authors: Angela Branche, Mark J. Mulligan, Alok Maniar, Orlando Puente, Islamiat Oladipupo, Graham Crowther, Agnieszka M. Zareba, Zhuobiao Yi, Ingrid Scully, Emily Gomme, Kenneth Koury, Nicholas Kitchin, Pirada Suphaphiphat Allen, Annaliesa S. Anderson, Alejandra Gurtman, Kelly Lindert
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Vaccines
Subjects:
influenza
vaccination
modRNA
immunogenicity
safety
tolerability
Online Access:https://www.mdpi.com/2076-393X/13/4/383
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items